Literature DB >> 28005230

Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.

Qing Zhang1, Wei Wang1, Bing Zhang2, Jong Shi3, Yao Fu3, Danyan Li2, Suhan Guo4, Shengjie Zhang1, Haifeng Huang1, Xuping Jiang5, Weimin Zhou5, Hongqian Guo6.   

Abstract

OBJECTIVES: To prospectively compare biopsy outcomes between free-hand transperineal mpMRI/TRUS fusion targeted biopsy (TB) and transperineal systematic biopsy (SB) in patients with first prostate biopsy. PATIENTS AND METHODS: In all, 224 consecutive patients with the suspicion of PCa were investigated. All patients were evaluated by 3.0-T mpMRI applying the ESUR criteria. All patients underwent free-hand transperineal mpMRI/TRUS fusion TB and additionally a transperineal SB. Pathological findings of TB, SB, and step-sectioned RP specimens were analyzed.
RESULTS: The median age of the patients was 69 (40-85) years, median PSA level was 10.05 (3.61-78.39) ng/mL, and median prostate volume was 45.5 (22-77) mL. Overall, the PCa detection rate was 50.45% (113/224). TB detected significantly more cancer [44.2% (99/224) vs. 34.8% (78/224); P = 0.001] and clinically significant PCa [75.75% (75/99) vs. 62.82% (49/78); P = 0.005] than SB. For the upgrading of Gleason score, 39.74% (31/78), more clinically significant PCa was detected by using additional TB than by SB alone. Conversely, 5.05% (5/99) more clinically significant PCa was found by SB in addition to that by TB. The location of 96.67% (58/60) and Gleason score of 60% (36/60) of TB-proven ITs were correctly identified, as corroborated by RP specimens. The median IT volume was 1.125 (0.21-19.87) ml on MRI and 1.41 (0.13-9.56) ml in RP specimens.
CONCLUSIONS: Free-hand transperineal mpMRI/TRUS fusion biopsy was associated with a higher detection rate of clinically significant PCa while taking fewer cores. Moreover, this technique can reliably predict the location, and relatively reliably predict cancer volume and Gleason score of ITs.

Entities:  

Keywords:  Index tumor; Location; Prostate cancer; Targeted biopsy; mpMRI/TRUS fusion

Mesh:

Substances:

Year:  2016        PMID: 28005230     DOI: 10.1007/s11255-016-1484-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  29 in total

1.  Gleason score 6 adenocarcinoma: should it be labeled as cancer?

Authors:  H Ballentine Carter; Alan W Partin; Patrick C Walsh; Bruce J Trock; Robert W Veltri; William G Nelson; Donald S Coffey; Eric A Singer; Jonathan I Epstein
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

2.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

3.  Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.

Authors:  Neil Mendhiratta; Andrew B Rosenkrantz; Xiaosong Meng; James S Wysock; Michael Fenstermaker; Richard Huang; Fang-Ming Deng; Jonathan Melamed; Ming Zhou; William C Huang; Herbert Lepor; Samir S Taneja
Journal:  J Urol       Date:  2015-06-19       Impact factor: 7.450

4.  Correlation of magnetic resonance imaging tumor volume with histopathology.

Authors:  Baris Turkbey; Haresh Mani; Omer Aras; Ardeshir R Rastinehad; Vijay Shah; Marcelino Bernardo; Thomas Pohida; Dagane Daar; Compton Benjamin; Yolanda L McKinney; W Marston Linehan; Bradford J Wood; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

5.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

6.  Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Authors:  James E Thompson; Daniel Moses; Ron Shnier; Phillip Brenner; Warick Delprado; Lee Ponsky; Marley Pulbrook; Maret Böhm; Anne-Maree Haynes; Andrew Hayen; Phillip D Stricker
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

Review 7.  Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?

Authors:  Hashim Uddin Ahmed; Manit Arya; Alex Freeman; Mark Emberton
Journal:  Lancet Oncol       Date:  2012-11       Impact factor: 41.316

8.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.

Authors:  T A Stamey; F S Freiha; J E McNeal; E A Redwine; A S Whittemore; H P Schmid
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

9.  Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies.

Authors:  Sascha Kaufmann; Stephan Kruck; Ulrich Kramer; Sergios Gatidis; Arnulf Stenzl; Matthias Roethke; Marcus Scharpf; David Schilling
Journal:  Urol Int       Date:  2014-09-13       Impact factor: 2.089

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  13 in total

1.  From novice to expert: analyzing the learning curve for MRI-transrectal ultrasonography fusion-guided transrectal prostate biopsy.

Authors:  R Mager; M P Brandt; H Borgmann; K M Gust; A Haferkamp; M Kurosch
Journal:  Int Urol Nephrol       Date:  2017-06-23       Impact factor: 2.370

2.  Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.

Authors:  Mengxia Chen; Qing Zhang; Chengwei Zhang; Xiaozhi Zhao; Giancarlo Marra; Jie Gao; Xiaoyu Lv; Bing Zhang; Yao Fu; Feng Wang; Xuefeng Qiu; Hongqian Guo
Journal:  J Nucl Med       Date:  2018-12-14       Impact factor: 10.057

3.  Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?

Authors:  Haoli Yin; Mengxia Chen; Xuefeng Qiu; Li Qiu; Jie Gao; Danyan Li; Yao Fu; Haifeng Huang; Suhan Guo; Qing Zhang; Shuyue Ai; Feng Wang; Hongqian Guo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-04       Impact factor: 9.236

4.  Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline.

Authors:  Masoom A Haider; Judy Brown; Jospeh L K Chin; Nauthan Perlis; Nicola Schieda; Andrew Loblaw
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

5.  Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?

Authors:  Jakob Schlegel; Stefan Hinz; Karsten Günzel; Ahmed Magheli; Jonas Busch; Eduard Baco; Hannes Cash; Stefan Heinrich; Daniela Edler; Martin Schostak; Hendrik Borgmann
Journal:  Int Urol Nephrol       Date:  2022-07-25       Impact factor: 2.266

6.  Preliminary study on ultrasound-guided prostate biopsy specimen scores.

Authors:  Cheng Li; Weiwei Zhan; Minguang Zhang; Fangxiu Luo; Yan Wang; Bin Zheng
Journal:  Exp Ther Med       Date:  2017-07-18       Impact factor: 2.447

Review 7.  MRI-targeted prostate biopsy: the next step forward!

Authors:  Emanuel Darius Cata; Iulia Andras; Teodora Telecan; Attila Tamas-Szora; Radu-Tudor Coman; Dan-Vasile Stanca; Ioan Coman; Nicolae Crisan
Journal:  Med Pharm Rep       Date:  2021-04-29

8.  The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens.

Authors:  Zhipeng Mai; Zhien Zhou; Weigang Yan; Yu Xiao; Yi Zhou; Zhiyong Liang; Zhigang Ji; Hanzhong Li
Journal:  BMC Cancer       Date:  2018-12-04       Impact factor: 4.430

9.  Diagnostic Value of 68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study.

Authors:  BaoJun Wang; Jie Gao; Qing Zhang; Yao Fu; Guangxiang Liu; Jiong Shi; Danyan Li; Feng Wang; Hongqian Guo
Journal:  J Nucl Med       Date:  2019-11-22       Impact factor: 11.082

10.  Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.

Authors:  Qing Zhang; Shiming Zang; Chengwei Zhang; Yao Fu; Xiaoyu Lv; Qinglei Zhang; Yongming Deng; Chuan Zhang; Rui Luo; Xiaozhi Zhao; Wei Wang; Feng Wang; Hongqian Guo
Journal:  J Transl Med       Date:  2017-11-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.